Showing results (11-20 of 30) with videos related to
Sort By:
Pageof 3
European Urology|May 22, 2012
Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?Grace L Lu-Yao, Peter C Albertsen, Hui Li, et al.Journal of the American College of Surgeons|March 2, 2005
Detection of B-RAF and N-RAS mutations in human melanomaJames S Goydos, Barbara Mann, Hyunjin J Kim, et al.European Urology|June 14, 2013
Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysisYu-Hsuan Joni Shao, Sung Kim, Dirk F Moore, et al.Cancer Prevention Research (Philadelphia, Pa.)|February 28, 2012
δ- and γ-tocopherols, but not α-tocopherol, inhibit colon carcinogenesis in azoxymethane-treated F344 ratsFei Guan, Guangxun Li, Anna B Liu, et al.Journal of the National Cancer Institute|August 29, 2009
Contemporary risk profile of prostate cancer in the United StatesYu-Hsuan Shao, Kitaw Demissie, Weichung Shih, et al.Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|August 28, 2003
A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancyDeborah L Toppmeyer, Murugesan Gounder, Judie Much, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2003
Detection of mutations in the mitogen-activated protein kinase pathway in human melanomaJanivette Alsina, David H Gorsk, F Joseph Germino, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4Judy Bash-Babula, Deborah Toppmeyer, Marie Labassi, et al.Future Oncology (London, England)|August 4, 2022
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemiaSrdan Verstovsek, Norio Komatsu, Harinder Gill, et al.Anti-Cancer Drugs|May 6, 2008
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemiaBiren Saraiya, Murugesan Gounder, Jayeeta Dutta, et al.Pageof 3